Related Experiment Video
Updated: Feb 10, 2026

Bioassays for Monitoring Insecticide Resistance
Published on: December 30, 2010
Combining Biomonitoring Data and a Pharmacokinetic Model to Estimate the Extended Half-Life of Neonicotinoid
Tao Zhang1, Henglin Zhang1, Tianhui Zhao2
1School of Agriculture and Biotechnology, Sun Yat-sen University, Shenzhen 518107, China.
None:
Neonicotinoid insecticides (NEOs) are globally prevalent environmental contaminants. However, their biological half-lives in humans remain poorly characterized. This study employed a controlled mouse pharmacokinetic experiment with human biomonitoring data to elucidate key parameters for selected NEOs. Human biomonitoring provided renal clearance (CLrenal), while controlled mice experiment provided the volume of distribution (Vd); these were combined to estimate the biological half-life. Analysis of 172 paired human urine and blood samples revealed that CLrenal varied substantially among parent NEOs (median: 9.04 to 158 mL/day/kg) and exhibited a distinct structure-dependency. The CLrenal of fused, bicyclic NEOs (i.e., imidacloprid (IMI), thiacloprid (THD), and thiamethoxam (THM)) was governed by water solubility, while that of their nonfused, monocyclic systems (i.e., acetamiprid (ACE), clothianidin (CLO), and dinotefuran (DIN)) was determined by lipophilicity. A one-compartment log-linear regression analysis of intravenous mice data provided robust estimates of Vd, which ranged from 306 to 700 mL/kg body weight for ACE, IMI, and DIN. By combining Vd with human CLrenal, the extrapolated median biological half-life for ACE, IMI, and DIN were 15.5, 24.8, and 53.7 days, respectively, indicating significant potential for bioaccumulation in humans. Uncertainty analysis and sensitivity analyses confirmed the robustness of these prolonged estimates, yielding 95% confidence intervals of 5.53 (ACE) to 157 (DIN) days, with even the most conservative scenario giving a range of 5.17 (ACE) to 17.9 (DIN) days. The prolonged half-life of NEOs indicates a significant potential for bioaccumulation in humans upon continuous exposure, which warrants further investigation regarding its implications for human health risk assessment.
More Related Videos
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model Approaches for Pharmacokinetic Data: Physiological Models
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis of Population Pharmacokinetic Data

